Wedbush Maintains Outperform on BioCryst Pharma, Lowers Price Target to $21

Benzinga Newsdesk www.benzinga.com Negative 94.4%

Neg 94.4% Neu 0% Pos 0%

Wedbush analyst Laura Chico maintains BioCryst Pharma (NASDAQ:BCRX) with a Outperform and lowers the price target from $22 to $21.